Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription 20.10.2025 2 Am J Hematol 4 Ann Hematol 3 Blood 1 BMC Cancer 1 Bone Marrow Transplant 1 Cancer 1 Exp Cell Res 3 Hematol Oncol Clin North Am 1 J Clin Oncol 1 Leuk Lymphoma 1 Leuk Res 1 Oncol Rep 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. 
   Abstracts from the 2025 Lymphoma Leukemia and Myeloma Congress October 14-17, 2025.
   Am J Hematol. 2025;100 Suppl 5:S3-S80.
   PubMed        
   
   
2. ALDOSS I, Ali A, Cassaday RD, Curran EK, et al
   Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations.
   Am J Hematol. 2025 Oct 11. doi: 10.1002/ajh.70103.
   PubMed         Abstract available
   
   

   
   Ann Hematol

3. KIM M, Song IC, Ahn SY, Jang HC, et al
   Cytogenetic risk-associated outcomes of antithymocyte globulin use in HLA-matched sibling transplantation for acute myeloid leukemia.
   Ann Hematol. 2025 Oct 16. doi: 10.1007/s00277-025-06608.
   PubMed         Abstract available
   
   
4. TANG S, Sheng L, Mu Q, Wang Y, et al
   NIPA1 depletion in tumor-associated macrophages via IGFBP2/EGFR attenuates acute myeloid leukemia progression and chemoresistance.
   Ann Hematol. 2025 Oct 14. doi: 10.1007/s00277-025-06688.
   PubMed         Abstract available
   
   
5. QUINQUENEL A, Lepretre S, Dilhuydy MS, Bussot L, et al
   Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).
   Ann Hematol. 2025 Oct 13. doi: 10.1007/s00277-025-06632.
   PubMed        
   
   
6. FAN H, Yang Y, Lu Y, Li J, et al
   Global burden of acute lymphoblastic leukemia following the COVID-19 pandemic.
   Ann Hematol. 2025 Oct 11. doi: 10.1007/s00277-025-06639.
   PubMed         Abstract available
   
   

   
   Blood

7. HANTEL A, Wang Y, Cronin A, Khan I, et al
   Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials.
   Blood. 2025 Oct 16:blood.2025030741. doi: 10.1182/blood.2025030741.
   PubMed         Abstract available
   
   
8. CHIRIAC R
   Acute myeloid leukemia mimicking mature lymphoid morphology.
   Blood. 2025;146:2005.
   PubMed        
   
   
9. GUO M, Memis T, Ehrmann AS, Pittrof A, et al
   A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL.
   Blood. 2025;146:1936-1949.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. PINAR IE, Celik S, Polat MG, Karatas AF, et al
    Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project.
    BMC Cancer. 2025;25:1546.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

11. NAGLER A, Esteve J, Galimard JE, Sanz J, et al
    Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry.
    Bone Marrow Transplant. 2025 Oct 16. doi: 10.1038/s41409-025-02727.
    PubMed         Abstract available
    
    

    
    Cancer

12. SICURANZA A, Pacelli P, Santoni A, Abruzzese E, et al
    Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study.
    Cancer. 2025;131:e70122.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

13. GE H, Bai H, Yu J, Cheng J, et al
    The BET degrader BETd-246 demonstrated significant anti-tumor efficacy in T-cell acute lymphoblastic leukemia by inhibiting TRAT1.
    Exp Cell Res. 2025 Oct 9:114791. doi: 10.1016/j.yexcr.2025.114791.
    PubMed         Abstract available
    
    

    
    Hematol Oncol Clin North Am

14. HUANG J, Shadman M
    First-line Therapy: Time-Limited Venetoclax Doublet Therapy.
    Hematol Oncol Clin North Am. 2025;39:885-901.
    PubMed         Abstract available
    
    
15. BROWN JR
    Resistance to Bruton Tyrosine Kinase Inhibitors.
    Hematol Oncol Clin North Am. 2025;39:951-963.
    PubMed         Abstract available
    
    
16. THOMPSON PA, Parry EM
    Advances in the Understanding of Richter Transformation.
    Hematol Oncol Clin North Am. 2025;39:997-1012.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

17. MONTESINOS P, Rodriguez-Veiga R, Bergua JM, Algarra Algarra JL, et al
    Quizartinib for Newly Diagnosed FLT3-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study.
    J Clin Oncol. 2025 Oct 13:101200JCO2501841. doi: 10.1200/JCO-25-01841.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

18. LIN J, He C, Cai Z, Chen J, et al
    Pediatric-inspired regimen abrogates the poor prognosis of adult early T-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Oct 16:1-8. doi: 10.1080/10428194.2025.2558921.
    PubMed         Abstract available
    
    

    
    Leuk Res

19. UNAL D, Gumruk F, Aytac S, Kuskonmaz B, et al
    Infectious complications in pediatric acute lymphoblastic leukemia treatment: A comparison of ALL-IC BFM 2009 vs. modified St. Jude total XV in a single-center retrospective cohort study.
    Leuk Res. 2025;158:108120.
    PubMed         Abstract available
    
    

    
    Oncol Rep

20. JIANATI R, Chen H, Yang X, Yan L, et al
    Targeting cell death pathways in acute myeloid leukemia: Molecular mechanisms and clinical implications (Review).
    Oncol Rep. 2025;54:172.
    PubMed         Abstract available
    
    

    
    PLoS One

21. NASRI F, Jalaeikhoo H, Dadmanesh M, Behranvand N, et al
    Comparison the impact of IFN-beta alone or in combination with vitamin D on critical pathways involved in AML progression.
    PLoS One. 2025;20:e0330865.
    PubMed         Abstract available
    
    
22. XU X, Ge X, Jiang A, Chen J, et al
    HLF gene is a poor prognostic factor in acute myeloid leukemia patients with FLT3-ITD/NPM1 mutations undergoing hematopoietic transplantation.
    PLoS One. 2025;20:e0333690.
    PubMed         Abstract available
    
    
23. BUDHA B, Basu Choudhury G, Hossain MS, Acharya A, et al
    Structure-guided discovery and characterization of novel FLT3 inhibitors for acute myeloid leukemia treatment.
    PLoS One. 2025;20:e0334415.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.